Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study. Read More
Lila Biologics hopes to hand off a candidate protein within three to six months so the pharmaceutical giant can take the drug through clinical trials. Read More
The Seattle-based Infectious Disease Research Institute (IDRI), a product-focused nonprofit that fights infectious diseases around the world, announced today that… Read More
Don't miss a headline!
Sign up for GeekWire's newsletters today.
Thanks for subscribing!
Check your inbox to confirm your subscription.
